Երկիր: Իռլանդիա
Լեզու: անգլերեն
Աղբյուրը: HPRA (Health Products Regulatory Authority)
Prednisolone
Chemidex Pharma Limited
D07AA; D07AA03
Prednisolone
20 milligram(s)
Rectal foam
Corticosteroids, weak (group I); prednisolone
Marketed
2011-02-11
IR3-1/L/z/5 PACKAGE LEAFLET: INFORMATION FOR THE USER PREDNISOLONE 20 MG RECTAL FOAM PREDNISOLONE as Prednisolone Metasulphobenzoate Sodium READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Prednisolone 20 mg Rectal Foam is and what it is used for 2. What you need to know before you use Prednisolone 20 mg Rectal Foam 3. How to use Prednisolone 20 mg Rectal Foam 4. Possible side effects 5. How to store Prednisolone 20 mg Rectal Foam 6. Contents of the pack and other information 1. WHAT PREDNISOLONE 20 MG RECTAL FOAM IS AND WHAT IT IS USED FOR Prednisolone 20 mg Rectal Foam is a foam enema which is inserted into the rectum. Prednisolone 20 mg Rectal Foam belongs to a group of medicines called corticosteroids which are used to reduce inflammation. This medicine is used to treat ulcerative colitis (inflammation of the bowels) and may be used to treat proctitis (inflammation of the rectum). 2. WHAT YOU NEED TO KNOW BEFORE YOU USE PREDNISOLONE 20 MG RECTAL FOAM DO NOT USE PREDNISOLONE 20 MG RECTAL FOAM: • If you are allergic to prednisolone or any of the other ingredients of this medicine (listed in section 6). • If you suffer from peritonitis (inflammation of the peritoneum – (abdominal lining)). • If you suffer from bowel problems such as obstruction, perforation or rectal/colonic fistulae (abnormal connection between internal organs) or if you have a possible infection. If you think this may apply to you speak to your doctor. WARNINGS AND PRECAUTIONS TALK TO YOUR DOCTOR BEFORE US Կարդացեք ամբողջական փաստաթուղթը
Health Products Regulatory Authority 05 April 2023 CRN00DHG0 Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Prednisolone 20 mg Rectal Foam 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose contains 31.4mg of the active ingredient prednisolone metasulphobenzoate sodium, equivalent to prednisolone 20.0mg Excipients with known effect: Cetostearyl alcohol 4.4mg and Sorbic Acid 1.74mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Rectal Foam A white to pale cream coloured, metered-dose rectal foam. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of proctitis and ulcerative colitis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults and elderly patients: One metered dose rectally once or twice daily for 2 weeks, extending treatment for a further 2 weeks when a good response is obtained. Use should be discontinued at the discretion of the physician once the disease is stable and under control. Paediatric population: Not recommended. Shake canister before use. When using for the first time remove and discard the small plastic safety tag from under the button. An applicator nozzle is then pushed onto the side arm of the canister. The semi-circular cut-out on the cap is lined up with the nozzle. The easiest way to administer Prednisolone 20 mg Rectal Foam is to stand with one foot raised on a chair and gently insert the nozzle tip into the rectum. Smearing the nozzle with lubricating jelly may help insertion. Holding the canister with the dose button pointing down, press the button on the canister firmly and release. Only press the button once so as not to exceed the recommended dose. Method of administration: For rectal administration only. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients. Health Products Regulatory Authority 05 April 2023 CRN00DHG0 Page 2 of 4 Local conditions where infection might be masked or healing impaired, e.g. peritonitis, fistulae, intestinal obstruction, perf Կարդացեք ամբողջական փաստաթուղթը